[Ischemic disease of the kidneys in a patient with morbid obesity: characteristics of the course and diagnostic policy].
Fomin
V V
VV
Safonov
V V
VV
Kozlovskaia
N L
NL
Moiseev
S V
SV
Osipenko
V I
VI
Tironishvili
O I
OI
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006291:Health Policy; D006801:Humans; D007511:Ischemia / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D007674:Kidney Diseases / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D009765:Obesity / Q000150:complications*
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D008790:Metoprolol; D009543:Nifedipine